Only the symptoms of ataxia, such as weakness and mobility issues, may be treated as the disease has no known treatment. Spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and other kinds of ataxia exist. Ataxia is becoming more common. In the pharmaceutical sector, key companies are focused on filing applications for approval of medicines therapy for the treatment of ataxia, which is likely to fuel growth in the global ataxia market throughout the forecast period. The rarity of ataxia illness is a key impediment to performing clinical studies for its treatment, which is projected to stymie growth in the worldwide ataxia market throughout the forecast period. Because of the link of ataxia with COVID-19, the COVID-19 pandemic is projected to have a favourable influence on the worldwide ataxia market. According to a March 2021 article published in the journal Movement Disorders Clinical Practice, several neurological manifestations of COVID-19 have been reported globally, ranging from mild conditions such as headache, confusion, focal seizures, ataxia to severe life-threatening conditions such as Guillain Barre Syndrome, acute haemorrhagic necrotizing encephalopathy, and others.
According to Coherent Market Insights, the global Ataxia Market is estimated to be valued at US$ 30,880.5 million in 2021 and is expected to exhibit a CAGR of 9.4% over the forecast period (2021-2028).
Key Competitors in the Ataxia Industry:
1. Pfizer, Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide
2. CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
3. Acorda Therapeutics
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
4. Capsida Biotherapeutics Inc.
Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders. It features a proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the diseased organ. The company is headquartered in U.S., founded in 2019.
5. Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. The company was founded in 2005.
6. Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
7. Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries.
8. Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
9. GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GSK plc and Wave
10. Allergan
Allergan, is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential to see more clearly, move more freely, express themselves more fully. In 1950, pharmacist Gavin S. Herbert established Allergan Pharmaceuticals, Inc. Allergan focused on the discovery and development of novel formulations for specialty markets, as well as intimate collaboration with physicians and the scientific community. In 1953, Allergan produced eye drops and formulated new products such as the first cortisone eye drop to treat allergic inflammation and the first ophthalmic steroid decongestant. Allergan's is best known for its product, Botox. Some of the top Botox providers in the U.S. Include Epione Beverly Hills, EVEXIAS Medical Centers & Skin Associates.
*Definition - A series of degenerative conditions known as ataxia affect the cerebellum, a region of the brain that controls bodily balance and coordination.
